ENANTA PHARMACEUTICALS INC
NASDAQ: ENTA (Enanta Pharmaceuticals, Inc.)
Kemas kini terakhir: semalam, 1:24AM11.00
0.92 (9.13%)
| Penutupan Terdahulu | 10.08 |
| Jumlah Dagangan | 320,115 |
| Harga / Jualan (P/S) | 4.42 |
| Harga / Buku (P/B) | 3.07 |
| Julat 52 Minggu |
| Margin Keuntungan | -149.57% |
| Margin Operasi (TTM) | -164.32% |
| EPS Cair (TTM) | -4.53 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -12.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 231.07% |
| Nisbah Semasa (MRQ) | 5.29 |
| Aliran Tunai Operasi (OCF TTM) | -55.46 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -72.37 M |
| Pulangan Atas Aset (ROA TTM) | -17.33% |
| Pulangan Atas Ekuiti (ROE TTM) | -74.26% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Enanta Pharmaceuticals, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Nilai 35% | -2.5 |
| AI Insight info | NA |
| Penilaian Relatif info | NA |
| Kesihatan Kewangan info | -2.5 |
| Masa 35% | -1.5 |
| AI Technical info | NA |
| Osilator Teknikal info | -2.5 |
| Purata Bergerak Teknikal info | 0.0 |
| Wang Pintar 30% | 0.0 |
| Konsensus Penganalisis info | 0.0 |
| Aktiviti Orang Dalam info | NA |
| Persekitaran | ×1.21 |
| Persekitaran Makro info | -3.3 |
| Sektor berbanding Pasaran (6B) | -36.3% |
| Persetujuan Tonggak | ×1.25 |
| Tidak dikira dalam skor | |
| Volatiliti Harga info | 2.9 |
| Skor Akhir | -2.12 |
|
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 6.57% |
| % Dimiliki oleh Institusi | 87.24% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Krensavage Asset Management, Llc | 30 Jun 2026 | 2,866,138 |
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |